All Stories

  1. Metabolomics of Multiple System Atrophy Patient-Derived Striatal Medium Spiny Neurons
  2. Sex-Independent Upregulation of miR-146a-5p in Parkinson’s Disease Patients: A Longitudinal Study
  3. The Emotional Landscape of Multiple System Atrophy: A Preliminary Personality-Based Perspective
  4. Artificial Intelligence Predicts GBA1 Mutated Status in Parkinson's Disease Patients
  5. Proteomics of Patient-Derived Striatal Medium Spiny Neurons in Multiple System Atrophy
  6. A Twisting Diagnosis: A New Case of VPS16‐Related Hyperkinetic Spectrum and Literature Review
  7. Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The EPIC Study
  8. RAB32-linked Parkinson’s disease: Deep phenotyping, MDSGene literature review, and application of SynNeurGe criteria
  9. Disease-modifying therapy in GBA1-related Parkinson's disease: the type of variant matters
  10. Gender Is the Main Predictor of Wearing‐Off and Dyskinesia in Levodopa‐Naïve Patients with Parkinson's Disease
  11. LONG-NEXT: A new accurate and efficient NGS-based method for GBA1 analysis in Parkinson disease
  12. 18F-FDG PET findings in Parkinson's disease associated to RAB32 S71R variant
  13. Reply: “Enhancing Parkinson's Disease Research: Recommendations for Addressing Genetic and Environmental Influences in Family History Studies”
  14. The Genetic Epidemiology of Parkinson's Disease view
  15. Adult‐Onset Dystonia‐Parkinsonism: Do Not Forget SERAC1
  16. Coenzyme Q10 deficiency disrupts lipid metabolism by altering cholesterol homeostasis in neurons
  17. A De Novo SCN2A Variant in a Patient with Adult‐Onset Dystonia Parkinsonism and Nigrostriatal Denervation
  18. Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia
  19. Oxidative Stress: A New Pathophysiological Pathway in Parkinson’s Disease and a Potential Target of the Brain‐Sport Crosstalk
  20. Distinctive cognitive phenotypes in Parkinson’s disease patients with GBA mutations and without dementia: a multicentre cross-sectional retrospective study
  21. Long-term motor and cognitive outcome of Deep Brain Stimulation in GBA-PD: the Italian PARKNET study
  22. Childhood-onset focal epilepsy and acute para-infectious encephalopathy in a patient with biallelic QARS1 variants
  23. Lewy pathology formation in patient-derived GBA1 Parkinson’s disease midbrain organoids
  24. RAB32 mutation in Parkinson's disease
  25. RAB32 mutation in Parkinson's disease
  26. Dystonic Tremor as Main Clinical Manifestation of SCA21
  27. Obsessive-compulsive disorder as a first manifestation of Ataxia with Oculomotor Apraxia type 2 due to a novel mutation of SETX gene
  28. Neurosteroid Levels in GBA Mutated and Non-Mutated Parkinson’s Disease: A Possible Factor Influencing Clinical Phenotype?
  29. Neurosteroid Levels in GBA and Non-mutated PD: A Possible Factor Influencing Clinical Phenotype?
  30. Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease
  31. The p.Val234Met LRP10 likely pathogenic variant associated with Parkinson's disease: Possible molecular implications
  32. Supplementing Best Care with Specialized Rehabilitation Treatment in Parkinson’s Disease: A Retrospective Study by Different Expert Centers
  33. Soft cerebellar signs unveil RARS2‐related epilepsy
  34. A Case of 18p Chromosomal Deletion Encompassing GNAL in a Patient With Dystonia-Parkinsonism
  35. Unleashing the potential of mRNA therapeutics for inherited neurological diseases
  36. Comparing Essential Tremor with and without Soft Dystonic Signs and Tremor Combined with Dystonia: The TITAN Study
  37. Genotype–phenotype correlation in PRKN-associated Parkinson’s disease
  38. A Novel Pathogenic PSEN1 Variant in a Patient With Dystonia-Parkinsonism Without Dementia
  39. Genetics in Parkinson’s disease, state-of-the-art and future perspectives
  40. Response to: Are there two disjunct episignatures for KMT2B-related disease?
  41. Investigating the prevalence of MFN2 mutations in amyotrophic lateral sclerosis: insights from an Italian cohort
  42. Dominant VPS16 Pathogenic Variants: Not Only Isolated Dystonia
  43. Are patients with GBA–Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort
  44. Speech, Gait, and Vestibular Function in Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome
  45. Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study
  46. Editorial: Genetic advances and translational applications in movement disorders
  47. Clinical correlates of “pure” essential tremor: the TITAN study
  48. GABRB1‐related early onset developmental and epileptic encephalopathy: Clinical trajectory and novel de novo mutation
  49. Chorea‐Acanthocytosis Presenting with Parkinsonism‐Dystonia without Chorea
  50. Levodopa responsive asymmetric parkinsonism as clinical presentation of progranulin gene mutation.
  51. Dystonia Linked to EIF4A2 Haploinsufficiency: A Disorder of Protein Translation Dysfunction
  52. Don’t forget Allgrove syndrome in adult patients as a bulbar-ALS mimicker
  53. The unexpected finding of CNS autoantibodies in GBA1 mutation carriers with atypical parkinsonism
  54. A form of inherited hyperferritinemia associated with bi-allelic pathogenic variants of STAB1
  55. SCARB1 downregulation in adrenal insufficiency with Allgrove syndrome
  56. Kufor Rakeb syndrome without gaze palsy and pyramidal signs due to novel ATP13A2 mutations
  57. Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation
  58. Reply to: “Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort”
  59. Genetic Evidence for Endolysosomal Dysfunction in Parkinson’s Disease: A Critical Overview
  60. Whole-Exome Sequencing Study of Fibroblasts Derived From Patients With Cerebellar Ataxia Referred to Investigate CoQ10 Deficiency
  61. Deconstructing speech alterations in episodic ataxia type 2: Perceptual-acoustic analysis in a case due to CACNA1A gene mutation
  62. Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
  63. Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
  64. iPSC-Derived Striatal Medium Spiny Neurons from Patients with Multiple System Atrophy Show Hypoexcitability and Elevated α-Synuclein Release
  65. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms
  66. Tremulous spastic ataxia in a patient with a homozygous truncating SYNE1 variant
  67. Verbal Learning Impairment in Parkinson’s Disease: Role of the Frontostriatal System in Working and Strategic Memory
  68. Early-onset inherited dystonias versus late-onset idiopathic dystonias: Same or different biological mechanisms?
  69. Two cases of Huntington’s disease unmasked by the COVID-19 pandemic
  70. A sensitive method for determining UDP-glucose: ceramide glucosyltransferase (UGCG) activity in biological samples using deuterated glucosylceramide as acceptor substrate
  71. Anderson–Fabry Disease: A New Piece of the Lysosomal Puzzle in Parkinson Disease?
  72. BiallelicSTAB1pathogenic variants cause hereditary hyperferritinemia
  73. Nuclear Pore Complex Dysfunction in Dystonia Pathogenesis: Nucleoporins in the Spotlight
  74. Approaching the Gut and Nasal Microbiota in Parkinson’s Disease in the Era of the Seed Amplification Assays
  75. SCARB1 downregulation in adrenal insufficiency with Allgrove Syndrome
  76. Reply to: No Association between Rare TWNK Variants and Parkinson's Disease in European Cohorts
  77. Adult-onset KMT2B-related dystonia
  78. A Bayesian approach to Essential Tremor plus: A preliminary analysis of the TITAN cohort
  79. Juvenile-onset dystonia with spasticity in Leigh syndrome caused by a novel NDUFA10 variant
  80. Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease
  81. Trial of Cinpanemab in Early Parkinson’s Disease
  82. β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration
  83. Changes in non-motor symptoms in patients with Parkinson's disease following COVID-19 pandemic restrictions: A systematic review
  84. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease
  85. Case Report: Effect of Targeted Therapy With Carbamazepine in KCNQ2 Neonatal Epilepsy
  86. TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study
  87. The apparent paradox of phenotypic diversity and shared mechanisms across dystonia syndromes
  88. Axial improvement after casirivimab/imdevimab treatment for COVID-19 in Parkinson Disease
  89. Correction to: The Italian tremor Network (TITAN): rationale, design and preliminary findings
  90. Cognitive and Autonomic Dysfunction in Multiple System Atrophy Type P and C: A Comparative Study
  91. Genetic evaluation in phenotypically discordant monozygotic twins with Coats Disease
  92. The Italian tremor Network (TITAN): rationale, design and preliminary findings
  93. Clinical uses of Bupropion in patients with Parkinson’s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review
  94. Progressive myoclonus without epilepsy due to a NUS1 frameshift insertion: Dyssynergia cerebellaris myoclonica revisited
  95. Dysautonomia in Parkinson’s Disease: Impact of Glucocerebrosidase Gene Mutations on Cardiovascular Autonomic Control
  96. Transcriptomic characterization of tissues from patients and subsequent pathway analyses reveal biological pathways that are implicated in spastic ataxia
  97. Role of Lysosomal Gene Variants in Modulating GBA ‐Associated Parkinson's Disease Risk
  98. A Practical Approach to Early-Onset Parkinsonism
  99. Freezing of gait: overview on etiology, treatment, and future directions
  100. VPS13C-associated Parkinson's disease: Two novel cases and review of the literature
  101. Transcriptome deregulation of peripheral monocytes in GBA-related Parkinson’s disease
  102. Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories
  103. Parkinsonism and ataxia
  104. The activities of LRRK2 and GCase are positively correlated in clinical biospecimens and experimental models of Parkinson’s disease
  105. A 79-year-old man with unexplained recurrent syncope and severe orthostatic hypotension
  106. Sodium Levels Predict Disability at Discharge in Guillain-Barré Syndrome: A Retrospective Cohort Study
  107. Screening of LRP10 mutations in Parkinson's disease patients from Italy
  108. Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia
  109. HOPS-associated neurological disorders (HOPSANDs): linking endolysosomal dysfunction to the pathogenesis of dystonia
  110. Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis
  111. Targeting the Autonomic Nervous System for Risk Stratification, Outcome Prediction and Neuromodulation in Ischemic Stroke
  112. Clinical features and disease course of patients with acute ischaemic stroke just before the Italian index case: Was COVID-19 already there?
  113. A novel homozygous VPS11 variant may cause generalized dystonia
  114. Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review
  115. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  116. Expanding the genotypic and phenotypic spectrum of Beta‐propeller potein‐associated neurodegeneration
  117. A case report of late-onset cerebellar ataxia associated with a rare p.R342W TGM6 (SCA35) mutation
  118. A rapid and low-cost test for screening the most common Parkinson's disease-related GBA variants
  119. Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity
  120. The SPID-GBA study
  121. Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum
  122. Parkinson’s disease in Gaucher disease patients: what’s changing in the counseling and management of patients and their relatives?
  123. Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies
  124. GBA ‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort
  125. Late-onset leukoencephalopathy in a patient with recessive EARS2 mutations
  126. Nucleo–cytoplasmic transport defects and protein aggregates in neurodegeneration
  127. Design and Operation of the Lombardy Parkinson's Disease Network
  128. Pharmacological Antagonism of Kainate Receptor Rescues Dysfunction and Loss of Dopamine Neurons in a Mouse Model of Human Parkin-induced Toxicity 
  129. The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer’s Disease and Parkinson’s Disease
  130. Systemic involvement in adult‐onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome) with a novel mutation of SNORD118 gene
  131. SLC25A46 mutations in patients with Parkinson's Disease and optic atrophy
  132. Microscopic Polyangiitis With Selective Involvement of Central and Peripheral Nervous System: A Case Report
  133. Dystonia‐ataxia syndrome with permanent torsional nystagmus caused by ECHS1 deficiency
  134. Childhood onset dystonia with cerebellar signs: expanding the spectrum of GNAL mutations
  135. Loss of the nucleoporin Aladin in central nervous system and fibroblasts of Allgrove Syndrome
  136. Validation of the Italian version of the PSP Quality of Life questionnaire
  137. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives
  138. Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy
  139. Neurofascin (NFASC) gene mutation causes autosomal recessive ataxia with demyelinating neuropathy
  140. GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
  141. Parkinsonism in diseases predominantly presenting with dystonia
  142. Spinal direct current stimulation (tsDCS) in hereditary spastic paraplegias (HSP): A sham-controlled crossover study
  143. Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy
  144. Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy
  145. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study
  146. Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?
  147. Syncope and autonomic failure in a middle-aged man
  148. The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson’s Disease
  149. Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss
  150. In vitro models of multiple system atrophy from primary cells to induced pluripotent stem cells
  151. A de novo C19orf12 heterozygous mutation in a patient with MPAN
  152. Real life evaluation of safinamide effectiveness in Parkinson’s disease
  153. X-linked Parkinsonism with Intellectual Disability caused by novel mutations and somatic mosaicism in RAB39B gene
  154. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p
  155. Progressive Encephalomyelitis with Rigidity and Myoclonus Associated With Anti-GlyR Antibodies and Hodgkin’s Lymphoma: A Case Report
  156. Mutations in TMEM230 are rare in autosomal dominant Parkinson's disease
  157. Globus pallidus internus deep brain stimulation in PINK-1 related Parkinson's disease: A case report
  158. Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients
  159. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson’s Disease
  160. Mutational analysis of COQ2 in patients with MSA in Italy
  161. Autophagy in motor neuron disease: Key pathogenetic mechanisms and therapeutic targets
  162. Abnormal brain temperature in early-onset Parkinson's disease
  163. Cerebellar and Motor Cortical Transcranial Stimulation Decrease Levodopa-Induced Dyskinesias in Parkinson’s Disease
  164. Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation
  165. Designing geographical indication institutions when stakeholders’ incentives are not perfectly aligned
  166. Adaptive deep brain stimulation in patients with Parkinson’s disease: phase II clinical trial preliminary results
  167. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis
  168. Adaptive deep brain stimulation in a freely moving parkinsonian patient
  169. A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism
  170. Cerebellar tDCS: How to Do It
  171. Lower motor neuron disease with respiratory failure caused by a novel MAPT mutation
  172. Biochemical markers in early diagnosis and management of systemic amyloidoses
  173. Obesity and Headache/Migraine: The Importance of Weight Reduction through Lifestyle Modifications
  174. Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism
  175. Mutations in DNA2 Link Progressive Myopathy to Mitochondrial DNA Instability
  176. Congenital Myasthenic Syndrome Due to Choline Acetyltransferase Mutations in Infants
  177. The novel mitochondrial tRNAAsn gene mutation m.5709T>C produces ophthalmoparesis and respiratory impairment
  178. Two novel mutations in PEO1 (Twinkle) gene associated with chronic external ophthalmoplegia
  179. Unusual adult-onset Leigh syndrome presentation due to the mitochondrial m.9176T>C mutation
  180. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability
  181. Autosomal dominant restless legs syndrome maps to chromosome 20p13 (RLS-5) in a Dutch kindred
  182. GIGYF2 mutations are not a frequent cause of familial Parkinson's disease
  183. The Mitochondrial Disulfide Relay System Protein GFER Is Mutated in Autosomal-Recessive Myopathy with Cataract and Combined Respiratory-Chain Deficiency
  184. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome
  185. Pseudo-orthostatic and resting leg tremor in a large spanish family with homozygous truncating parkin mutation
  186. The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population
  187. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
  188. LRRK2 MUTATION ANALYSIS IN PARKINSON DISEASE FAMILIES WITH EVIDENCE OF LINKAGE TO PARK8
  189. SPG11: a consistent clinical phenotype in a family with homozygous Spatacsin truncating mutation
  190. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
  191. Parkin polymorphisms and environmental exposure: Decrease in age at onset of Parkinson's disease
  192. LRRK2 mutations and Parkinson's disease in Sardinia—A Mediterranean genetic isolate
  193. High prevalence ofLRRK2 mutations in familial and sporadic Parkinson's disease in Portugal
  194. Neuropathology of Parkinson's disease associated with theLRRK2 Ile1371Val mutation
  195. 1.283 Clinical and genetic study of a large Dutch family with autosomal dominant restless legs syndrome
  196. 2.119 Parkin polymorphisms and environmental exposure: Reduction of Parkinson's disease age of onset
  197. LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample
  198. The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence
  199. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan
  200. Striatal dopamine transporter binding in Parkinson's disease associated with theLRRK2 Gly2019Ser mutation
  201. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
  202. A case of CPT deficiency, homoplasmic mtDNA mutation and ragged red fibers at muscle biopsy
  203. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease
  204. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor
  205. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease
  206. POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions
  207. Remarkable infidelity of polymerase  A associated with mutations in POLG1 exonuclease domain
  208. Novel missense mutation and large deletion ofGNE gene in autosomal-recessive inclusion-body myopathy